Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

<sup>18</sup>F-PSMA-1007 PET/CT Demonstrates Higher Accuracy for Biochemically Recurrent Prostate Cancer Compared to Contemporary Conventional Imaging.

Advances in urology·2026

Same author

WC1/WC2-Sre1 Transcriptional Cascade Controls Predation and Chlamydospore Formation in the Nematode-Trapping Fungus Arthrobotrys flagrans.

Microbial biotechnology·2026

Same author

Spectral visualization of excitonic pair breaking at individual impurities in Ta<sub>2</sub>Pd<sub>3</sub>Te<sub>5</sub>.

Nature nanotechnology·2026

Same author

How will PLUDO, PSMAfore, SPLASH, and ECLIPSE Impact Prostate Cancer Management?

European urology focus·2026

Same author

Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadir.

Future oncology (London, England)·2026

Same author

Biomarkers for Precision Prognosis in Prostate Cancer: Imaging, Molecular, and Integrated Approaches.

Cancers·2026

Search research articles

Related Experiment Video

Updated: Oct 22, 2025

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

PSMA Theranostics: Current Landscape and Future Outlook.

Hanbo Zhang¹, Stella Koumna², Frédéric Pouliot³

¹Department of Medical Oncology and Hematology, University of Manitoba, Winnipeg, MB R3E 0V9, Canada.

|August 27, 2021

Summary

Prostate-specific membrane antigen (PSMA) theranostics are revolutionizing prostate cancer care. This approach optimizes management and offers new therapeutic strategies, soon to be a standard of care.

Keywords:

positron emission tomography prostate cancer prostate-specific membrane antigen radioligand therapy theranostics

More Related Videos

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Related Experiment Videos

Last Updated: Oct 22, 2025

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Area of Science:

Oncology
Nuclear Medicine
Radiopharmaceutical Therapy

Background:

Prostate-specific membrane antigen (PSMA) is a key molecular target for advanced prostate cancer diagnostics and therapeutics.
PSMA-targeted theranostics show significant promise in optimizing prostate cancer management and altering its disease course.

Purpose of the Study:

To review the contemporary and future landscape of PSMA theranostic applications in prostate cancer.
To highlight evolving evidence, combination strategies, and clinical trial data for PSMA-targeted agents.

Main Methods:

Comprehensive literature search of PubMed, Google Scholar, and clinicaltrials.gov up to June 2021.
Analysis of evidence for PSMA-targeted radiopharmaceuticals, combination therapies, and predictive biomarkers.
Overview of 17 key PSMA theranostic clinical trials and seven ongoing trials in oligometastatic disease.

Main Results:

PSMA theranostics are evolving, with various radiopharmaceutical agents showing promise in prostate cancer treatment.
PSMA and FDG PET/CT are emerging as predictive biomarkers for PSMA radioligand therapy effectiveness.
Significant clinical trial activity is underway, exploring PSMA theranostics across different stages of prostate cancer.

Conclusions:

PSMA theranostics are poised to become the standard of care for prostate cancer management.
Integration of nuclear medicine physicians into multidisciplinary teams is crucial for successful PSMA theranostic implementation.